09 SEPTEMBER 2021

Open Dialogue with Parkway Cancer Centre Haematologists


Open Dialogue with PCC Haematologists

Dr Teo Cheng Peng, Senior Consultant, Haematology
Dr Colin Phipps Diong, Senior Consultant, Haematology
Dr Lee Yuh Shan, Senior Consultant, Haematology
Dr Dawn Mya, Senior Consultant, Haematology

Revolutionary advances in the field of Haematology since the mid-1990s have led to better treatment outcomes, says Dr Teo Cheng Peng, Senior Consultant, Haematology. In the Open Dialogue with PCC Haematologists webinar, he is joined by the PCC Haematology team as they discuss the 3 common blood cancers: leukemia, lymphoma and multiple myeloma.

What is Haematology?

Haematology is the field of medicine relating to blood disorders.

Dr Colin began the dialogue with a talk on leukemia. He started by explaining the function of the bone marrow, or the blood “factory” of the body, which produces bone marrow stem cells that in turn form blood cells in the circulatory system.

Unfortunately, any one of these cells can become cancerous, explained Dr Colin.

The stage, development, and type of cell that becomes cancerous determines the type of blood cancer it will become. In leukemia, the cancer cells or the leukemic clone grow uncontrollably and prevent the normal function of the bone marrow.

Treating leukemia

Dr Colin emphasised that in this era of rapidly developing therapies, we need to remember that unlike novel treatments, the standard of care has a long track record of balancing risk and effectiveness, with known long-term side effects.

A general guide for how leukemia is treated is to give treatment that will kill as many blood cancer cells as possible, followed by maintenance of response. For chronic leukemias, oral targeted therapy is given so that patients can eventually lead normal lives while on medication. For acute leukemias, stem cell transplant (SCT) will need to be considered.

There are two types of SCTs: autologous and allogeneic. In autologous SCT, stem cells are taken from the same patient and reinfused after the patient has undergone chemotherapy, while in allogeneic SCT, stem cells come from a suitably matched donor.

Generally, the role of autologous SCT is to recapitulate the hematopoietic system and immune system. In comparison, the role of allogeneic SCT is to form normal cells as well as kill small amounts of leukemia cells once donor stem cells mature in the body.

One of the more recent developments in blood cancer treatment is CAR T-cell therapy. CAR T-cell therapy involves taking T-cells from the patient and modifying them in a laboratory setting to get them to recognise certain targets on certain cancers. Once this process is ready, these cells are re-infused into the patient.

Dr Colin noted that although CAR T-cell therapy is expensive and has caused deaths in early clinical trials, doctors now know how to preventively treat patients such that severe complications are minimised. While CAR T-cell therapy has shown to be effective, he reminded participants that it is a targeted therapy that can only be used for specific types of cancers. Currently, there are only two approved indications for CAR-T cell therapy: B-cell acute lymphoblastic leukemia and large B-cell lymphoma.

Multiple myeloma - things to know

Dr Dawn continued the dialogue with an overview of multiple myeloma—a blood cancer originating from plasma cells, a type of white blood cells which produce antibodies that protect the body from foreign antigens.

When these cells turn cancerous, they grow uncontrollably and form tumour masses which eventually destroy the bones. Bone marrow production is affected and patients suffer from low levels of blood cells. At the same time, cancerous plasma cells do not produce normal antibodies, causing patients to suffer from low immunity.

In Singapore, there are approximately 100 cases of multiple myeloma per year (2 per 100,000 of the population). Though incidence is low in young adults, it increases in age, peaking around 65–75 years old, with slight male predominance.

Dr Dawn explained that in its early (monoclonal gammopathy of unknown significance (MGUS)) and intermediate stages (smouldering multiple myeloma), patients may remain well with no symptoms and low levels of cancerous plasma cells.

This can go on for a few years until it eventually progresses to clinically significant multiple myeloma. As a result, many cases are already clinically significant when they present to doctors, with symptoms related to the condition. These include symptoms related to: destruction of bones, especially in the spine (e.g. bone pain); disruption of blood cell production (e.g. anaemia); and abnormal proteins in the blood and urine (e.g. kidney failure).

Diagnosis of multiple myeloma is usually done with a bone marrow biopsy; a study of plasma cells under the microscope; the detection of genetic abnormalities of plasma cells; and abnormal proteins in blood and urine tests.

Treating multiple myeloma

Multiple myeloma is usually treated with the aim of symptom control and achieving prolonged remission. Dr Dawn added that treatment should be supplemented with supportive care for holistic cancer management.

Currently, the definitive treatment for multiple myeloma involves killing myeloma cells with combination therapy—noting that chemotherapy is limited to certain turnpoints of the disease, while new classes of treatment like targeted therapy, immunomodulatory drugs and monoclonal antibodies are more commonly used in combination.

Typically, patients can receive treatment as an outpatient, and treatment is usually well tolerated.

To end her talk, Dr Dawn concluded that outcomes have improved tremendously and new drugs are being developed rapidly, offering balance between quality of life and effectiveness of treatment, with possibility of prolonged remission being achieved—making the management of multiple myeloma similar to chronic disease.

Lymphoma in 2021 and the future

Dr Lee Yuh Shan continued the dialogue with a last talk on lymphoma—a type of blood cancer involving the lymphatic system of the body.

In Singapore, lymphoma is the 5th and 6th most common cancer in males and females respectively. Causes and risk factors include: age; viral infection (HIV, Epstein Barr Virus (EBV), Hepatitis C); bacteria infection (helicobacter pylori); exposure to chemicals (agent orange); solid organ transplant; genetic predisposition; low immunity; and autoimmune disease on immunosuppression.

Lymphoma can be classified into two main subtypes: Hodgkin’s lymphoma and non-Hodgkin’s lymphoma (NHL). The most common lymphoma is diffuse large B-cell lymphoma (DLBCL), an aggressive type of B-cell NHL.

Generally, patients with lymphoma may present with lymph node swelling; unexplained fever and unintentional weight loss of more than 10%; night sweats (B-cell NHL symptom); low or high lymphocytes count; tiredness; difficulty in breathing; skin itchiness; stomach fullness; and constipation.

Lymphoma - diagnosis and treatment

Diagnosis of lymphoma usually involves a lymph node biopsy, biopsy of the skin or any other involved organs, bone marrow biopsy, PET-CT scan and flow cytometry among other tests to improve on diagnostic yield.

Different types of lymphoma have slightly different approaches to treatment and aims. As some types of lymphoma do not require treatment and only need monitoring, it is hence important to get the correct diagnosis of the lymphoma subtype by the pathologist.

Generally, combinations of antibodies, chemotherapy and checkpoint inhibitors are important in the management of Hodgkin’s lymphoma, while certain types of B-cell non-Hodgkin’s lymphoma such as follicular lymphoma can be managed with chemotherapy-free regimens. Stem cell transplants are usually reserved for second line treatment when patients have relapsed or refractory disease which did not respond to conventional chemotherapy.

Dr Lee ended his talk by reminding patients that with new developments in lymphoma treatment, personalised treatment that takes into consideration disease status, mutation of tumour and fitness of the patient, remains important.

5 Q&As with the HPCC aematology Team

  1. How likely is a person to get both leukemia and lymphoma at same time?

    In general, doctors will usually identify one disease that is causing all related symptoms. However, there are rare scenarios where a patient may have a separate disease.

  2. My parent passed away from leukemia. What are the chances of me getting the disease and how can I prevent it?

    Acute leukemia is not a heritable condition—though there are rare exceptions.

    Unlike diseases like lung cancer where modifiable risks can be reduced to prevent the disease, there is not much we know about the prevention of acute leukemia. It is thus important to undergo regular health screenings and observe any abnormalities in blood count levels.

  3. Should I seek treatment in a restructured hospital or a private hospital?

    The difference between seeking treatment in a restructured hospital or a private hospital largely lies in the level of personalised care you get during your treatment.

    Generally, as blood diseases require long-term management and follow-up, it is best to seek treatment where you can choose a doctor you are comfortable with, who has a subspecialty in your disease.

  4. What is the success rate for CAR T-cell therapy for B-cell ALL?

    Though the effectiveness of CAR T-cell therapy depends on which line of treatment you are receiving and how aggressive the disease is, generally CAR T-cell therapy alone can have good success rates in B-cell ALL, with a response rate of about 70%.

  5. How has COVID-19 changed the treatment paradigm for lymphoma?

    Typically, we will still treat aggressive lymphoma immediately. However, for indolent lymphoma such as CLL, we may start the patient on vaccination first well before treatment. We may also decide on how to monitor the patient and whether to delay maintenance to allow patients to undergo vaccination first.

POSTED IN Cancer Treatments
TAGS blood cancer, targeted therapy
READ MORE ABOUT Acute Myeloid Leukaemia (AML), Chronic Lymphocytic Leukaemia (CLL), Chronic Myeloid Leukaemia (CML), Hodgkin Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma